TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
Cytiva BioProcess R&D AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
13,084,681
|
12,787,611
|
17,011,724 |
| Financial expenses |
3,838
|
0
|
11,543 |
| Earnings before taxes |
4,068,394
|
6,021,750
|
9,901,946 |
| EBITDA |
12,511,744
|
12,264,229
|
16,485,575 |
| Total assets |
24,871,411
|
36,946,293
|
35,410,790 |
| Current assets |
9,360,279
|
14,935,355
|
13,172,016 |
| Current liabilities |
12,429,100
|
14,240,079
|
22,878,621 |
| Equity capital |
12,442,311
|
22,706,214
|
11,534,007 |
| - share capital |
100
|
100
|
100 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
50.0%
|
61.5%
|
32.6% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
31.1%
|
47.1%
|
58.2% |
| Return on assets (ROA) |
16.4%
|
16.3%
|
28.0% |
| Current ratio |
75.3%
|
104.9%
|
57.6% |
| Return on equity (ROE) |
32.7%
|
26.5%
|
85.9% |
| Change turnover |
297,070
|
-4,224,113
|
2,225,437 |
| Change turnover % |
2%
|
-25%
|
15% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.